The DOI matches its Crossref record; 349 of the 363 references it cites were found in a registry or an index; 20 of the 40 sources its claims cite were checked for support.
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
Open accessAbstract
Updated ISHLT consensus providing a framework for identifying candidates for lung transplantation and accounting for combinations of risk factors in candidacy selection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Partly supported · 6 No basis given · 4 Couldn’t confirm · 3 Own method · 1 Supported · 1 Sources not found · 1 No full text of the sources · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The ESC/ERS model also employs the assessment of risk using a multi-parametric comprehensive analysis of clinical variables.(284) Unlike REVEAL, this model avoids use of any non-modifiable criteria, and does not “weight” the variables according to their relative importance.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Partly supportedcites [284] Galiè, 2016, Eur Heart J sourceExperimental — accuracy not yet measured
Section 6.2.4 calls for a multidimensional, comprehensive assessment, and section 6.2.5 says overall assessment should guide decisions when variables fall into different risk categories. The claim that the model avoids any nonmodifiable criteria is too absolute: both sections say age, sex, and other factors not affected by therapy can modify risk. The passages do not explicitly specify whether variables receive numerical weights. (LLM, conf=0.85)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This trend reflects the expansion of acceptable donors and candidates made possible by clinical and scientific advances. Far fewer absolute contraindications for lung transplant candidacy exist now, compared to the time of publication of prior versions of this document, making the selection of candidates even more complex.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > INTRODUCTION:
What the sources say
- Partly supportedcites [2] Orens, 2006, International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The introduction says advances in technology and medical knowledge prompted updated candidate-selection guidelines, and the Relative contraindications section allows consideration of some candidates previously treated more restrictively. But our copy does not state that lung transplantation expanded worldwide because more donors became acceptable, nor does it explicitly say there are far fewer absolute contraindications than in 1998 or that selection has become more complex for that reason. No page numbers are available in our copy. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [3] Maurer, 1998, International guidelines for the selection of lung transplant candidates, Transplantation source
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Frailty, defined as a generalized vulnerability to stressors resulting from the presence of multiple physiologic deficits, is associated with an increased risk of waitlist and post-transplant mortality.(51–53) However, frailty in lung transplant candidates is often attributable to advanced lung disease and may improve following transplant.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > RISK FACTORS TO BE CONSIDERED: > Functional Status and Frailty:
What the sources say
- Partly supportedcites [51] Baldwin, 2017, Refining low physical activity measurement improves frailty assessment in advanced lung disease and survivors of critical illness, Ann Am Thorac Soc sourceExperimental — accuracy not yet measured
The Results (page unavailable) link frailty measured with FFP-DASI to increased death or delisting among lung-transplant candidates. The Methods (page unavailable) say participants were censored at transplant, so this study does not support the post-transplant mortality claim. The Abstract says no gold-standard frailty measure exists, but the paper does not specifically address using frailty measures for listing decisions. (LLM, conf=0.90)
- Supportedcites [52] Singer, 2018, Frailty phenotypes and mortality after lung transplantation: a prospective cohort study, Am J Transplant source
The Discussion states that frailty is associated with both waitlist and post-transplant mortality. It also says further work is needed to identify valid frailty measures before using them in organ allocation; the available passages do not give page numbers. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [53] Singer, 2015, Frailty phenotypes, disability, and outcomes in adult candidates for lung transplantation, Am J Respir Crit Care Med source
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Despite improved overall outcomes, many individuals with advanced CF lung disease remain at risk of short-term mortality. A 2017 study demonstrated a 10% risk of death each year after reaching an FEV1 < 30%, with many patients dying soon after reaching this threshold.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CYSTIC FIBROSIS
What the sources say
- Supportedcites [245] Ramos, 2017, Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 < 30% of predicted in the United States, Chest source
The Discussion reports improved survival but an approximately 10% annual probability of death once FEV1 falls below 30% predicted. The Conclusions add that some patients die soon after reaching that threshold, while others live for many years. (LLM, conf=0.92)
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant candidates must demonstrate abstinence from use of all tobacco and nicotine products (including nicotine replacement therapy) prior to transplant (e.g. with serial nicotine and cotinine screening).(111)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > PSYCHOSOCIAL RISK FACTORS: > Nicotine:
What the sources say
- Partly supportedcites [111] Hofmann, 2018, Smoking resumption after heart or lung transplantation: a systematic review and suggestions for screening and management, J Thorac Dis sourceExperimental — accuracy not yet measured
The Introduction says candidates are normally required to be smoke-free before joining a thoracic-transplant waiting list. But the systematic-screening section recommends cotinine testing at post-transplant follow-ups, not serial nicotine and cotinine testing before transplant. The paper also says nicotine replacement therapy can be used in transplant recipients; it does not establish the claimed pre-transplant ban on all nicotine products. (LLM, conf=0.88)
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Non-CF bronchiectasis represents 2.7% of all lung transplants reported to the ISHLT Registry between 1995–2018.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > NON-CYSTIC FIBROSIS BRONCHIECTASIS
What the sources say
- Could not verifycites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation—Indications section says Table 1 covers transplant indications since January 1995, but the passages available from our copy do not give a figure for non-CF bronchiectasis. Searches for “non-CF bronchiectasis,” “bronchiectasis,” and “2.7%” did not find the claimed proportion; the quoted passages instead discuss other indications and bronchiolitis obliterans syndrome. (LLM, conf=0.70)
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant for LAM is relatively rare; however, it is associated with better post-transplant survival compared to other advanced lung diseases.(1, 303–307)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > LYMPHANGIOLEIOMYOMATOSIS (LAM)
What the sources say
- Partly supportedcites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation section (page unavailable) reports that lymphangioleiomyomatosis as an indication for transplantation is favorably associated with survival in a multivariable model. It does not establish that LAM transplantation is relatively rare or recommend bilateral transplantation when organs are available; its favorable association for bilateral transplantation is reported separately, not specifically for LAM. (LLM, conf=0.87)
- Supportedcites [303] Ando, 2016, Lung Transplantation for lymphangioleiomyomatosis in Japan, PLoS One source
The Introduction describes LAM as rare and says it accounted for about 1% of heart or lung transplantation indications in an international survey. The Discussion reports that the Japanese LAM recipients had more favorable post-transplant survival than patients transplanted for other indications. The printed citing sentence does not make a claim about bilateral transplantation. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [304] Khawar, 2019, Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [305] Baldi, 2017, Experience of lung transplantation in patients with lymphangioleiomyomatosis at a Brazilian reference centre, Lung source
- Not checked — no full text of the sourcecites [306] Kurosaki, 2020, Favorable survival even with high disease-specific complication rates in lymphangioleiomyomatosis after lung transplantation-long-term follow-up of a Japanese center, Clin Respir J source
- Not checked — no full text of the sourcecites [307] Kpodonu, 2005, The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis, J Heart Lung Transplant source
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“An updated version of the score, REVEAL 2.0, which incorporates estimated GFR and all-cause hospitalizations within the previous six-months, has emerged as a powerful predictor of mortality and clinical worsening.(285–287) Neither of the REVEAL scores has been validated prospectively.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Not checked — no full text of the sourcecites [285] Benza, 2019, Predicting survival in patients with pulmonary arterial hypertension: The REVEAL Risk Score Calculator 2.0 and comparison with ESC/ERS-Based risk assessment strategies, Chest source
- Could not verifycites [286] Chakinala, 2018, Impact of declining renal function on outcomes in pulmonary arterial hypertension: a REVEAL registry analysis, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Discussion describes renal insufficiency as a mortality predictor included in the REVEAL risk score, and the Statistical analysis uses that score for adjustment. Our copy does not address REVEAL 2.0’s predictive performance or prospective validation (searched: REVEAL 2.0, clinical worsening, prospective validation). (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [287] Frost, 2013, Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis, Chest source
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung volume reduction (LVR), performed by either surgical or bronchoscopic approach, is an option for a subset of COPD patients with advanced emphysema who meet strict selection criteria. These procedures have been associated with improved lung function, exercise capacity, and quality of life.(181–183)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Partly supportedcites [181] Criner, 2019, Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). A multicenter, open-label randomized controlled clinical trial, Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Scientific Knowledge commentary says lung volume reduction surgery can improve lung function but is limited to eligible patients; the Results report improved lung function and health status after bronchoscopic valve treatment. The Results also say the improvement in exercise capacity was not statistically significant. The claim’s reference to delaying transplant is absent from the verbatim citing sentence and is not established by these passages. (LLM, conf=0.87)
- Partly supportedcites [182] Criner, 2018, A multicenter randomized controlled trial of Zephyr Endobronchial valve treatment in heterogeneous emphysema (LIBERATE), Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Introduction and Conclusion (pages not provided) describe surgical and bronchoscopic lung volume reduction as options for carefully selected patients with severe emphysema. The Discussion reports improvements in lung function, exercise capacity, and quality of life. The copy does not say these treatments delay transplantation; that point also does not appear in the verbatim citing sentence. (LLM, conf=0.85)
- Partly supportedcites [183] Fishman, 2003, A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion (p. 2071) reports that lung-volume-reduction surgery increased the chance of improved exercise capacity, lung function, and quality of life, with benefits varying by patient subgroup. The Methods (page not supplied) describe surgical approaches, not bronchoscopic reduction, so this paper does not support the sentence’s extension to both approaches. The citing sentence does not make a transplant-delay claim; the Treatment section reports transplant counts but does not establish that surgery delayed transplantation. (LLM, conf=0.87)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-min walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation. The BODE index has been cited as the prognostic model of choice by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and it formed the basis for listing recommendations in the 2014 ISHLT candidate selection guidelines. (4, 166–168)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [166] Celli, 2004, The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease, N Engl J Med source
- Partly supportedcites [167] Bellou, 2019, Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal, BMJ sourceExperimental — accuracy not yet measured
The external validation studies section reports that BODE was externally validated in 13 cohorts. The Principal findings in context section says GOLD uses BODE in clinical decision-making for lung transplantation, but our copy does not say that BODE formed the basis of the 2014 ISHLT listing recommendations. (LLM, conf=0.88)
- Not matchedcites [168] Disease GIfCOL: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2020 Report. 2020.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Active infections are generally contraindications for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In cases of CF and non-CF bronchiectasis, the colonization of resistant bacteria progresses, thereby increasing mortality after surgery.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although COPD remains the most common indication for lung transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation is possible despite infections with non-tuberculous mycobacteria, non-aspergillus molds, and Burkholderia cepacia complex if accompanied by appropriate treatment [3,26-28].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the BODE score (body mass index, degree of airway obstruction, dyspnea, and exercise capacity score) is still the most important indicator, and along with it, FEV1 and the presence or absence of acute exacerbation determine whether transplantation is possible based on the presence or absence of evidence for pulmonary arterial hypertension (PAH), as summarized in Table 2 [3,42].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current consensus is based on 2 tools for referral and listing: the REVEAL Registry 2.2 (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management 2.0) and 2015 European Society of Cardiology/European Respiratory Society.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Group 2, with decreased left ventricular function, is not an indication for transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the World Symposium of Pulmonary Hypertension classification of PAH, group 1 is the most common indication.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation may be necessary if prostacyclin treatment is required for an appropriate intervention, there is accompanying liver or renal failure, or severe hemoptysis is present [3,59-62]”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In 2021, the International Society for Heart and Lung Transplantation (ISHLT) published a new consensus document for selecting candidates for lung transplantation [3].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“group 3 with PAH and accompanying pathological changes in the lung parenchyma can be considered for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The use of immunosuppressive drugs after transplantation may lead to poor control of infection and progression to sepsis.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
Citations
Cites
Principles of Biomedical Ethics
(2012) · Thieves of Virtue · doi:10.7551/mitpress/9079.003.0009 · Cited by 13,453
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,730
Acute Respiratory Distress Syndrome
Ards Definition Task Force (2012) · JAMA · doi:10.1001/jama.2012.5669 · Cited by 9,066
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030287 · Cited by 2,071 · cited 2×
“…benefit has been demonstrated in a select group of patients with upper lobe predominant emphysema and low exercise capacity who undergo surgical LVR. 183 184-187 Prior LVR surgery can lead to formation of pleural adhesions, which can pose technical challenges to the surgeon at the time of…”
Background
Research works printed but not linked: 1
- Kulig, 2017, Interpretation of workplace tests for cannabinoids, J Med Toxicol, 13, 106, 10.1007/s13181-016-0587-z · DOI · Paper page
Cited by
Sorted by citations
Wijsenbeek, M. S., Suzuki, A., & Maher, T. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01052-2 · Cited by 576
Self-citationMaher, T. M. (2024) · JAMA · doi:10.1001/jama.2024.3669 · Cited by 435
Idiopathic pulmonary fibrosis: state of the art for 2023
Podolanczuk, A. J., Thomson, C. C., Remy-Jardin, M., Richeldi, L., Martinez, F. J., Kolb, M., & Raghu, G. (2023) · European Respiratory Journal · doi:10.1183/13993003.00957-2022 · Cited by 359
Bhakta, N. R., Bime, C., Kaminsky, D. A., McCormack, M. C., Thakur, N., Stanojevic, S., Baugh, A. D., Braun, L., Lovinsky‐Desir, S., Adamson, R., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202302-0310st · Cited by 316
“…is not used in the lung allocation score, the timing and listing for lung transplantation depends on — although it is not exclusively dependent on — FEV 1 (for COPD, cystic fi brosis, and lymphangioleiomyomatosis) and FVC (for interstitial lung disease) as a percentage of the predicted value (92).”
Progressive pulmonary fibrosis: an expert group consensus statement
Rajan, S. K., Cottin, V., Dhar, R., Danoff, S. K., Flaherty, K. R., Brown, K. K., Mohan, A., Renzoni, E. A., Mohan, M., V, Udwadia, Z., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.03187-2021 · Cited by 271
Agarwal, R., Sehgal, I. S., Muthu, V., Denning, D. W., Chakrabarti, A., Kathirvel, S., Garg, M. K., Rudramurthy, S. M., Dhooria, S., Armstrong-James, D. P. H., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.00061-2024 · Cited by 291
“The International Society for Heart and Lung Transplantation criteria should be used to refer and list patients with advanced ABPA [172].”
Pulmonary fibrosis: from pathogenesis to clinical decision-making
Koudstaal, T., Funke-Chambour, M., Kreuter, M., Molyneaux, P. L., & Wijsenbeek, M. S. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.08.010 · Cited by 273
Self-citationPeled, Y., Ducharme, A., Kittleson, M. M., Bansal, N., Stehlik, J., Amdani, S. M., Saeed, D., Cheng, R., Clarke, B. A., Dobbels, F., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.05.010 · Cited by 279
Boucly, A., Weatherald, J. C., Savale, L., de Groote, P., Cottin, V., Prévôt, G., Chaouat, A., Picard, F., Horeau-Langlard, D., BOURDIN, A. A., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02419-2021 · Cited by 211
Mall, M. A., Burgel, P., Castellani, C., Davies, J. C., Salathe, M. A., & Taylor‐Cousar, J. L. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00538-6 · Cited by 236
Olsson, K. M., Corte, T. J., Kamp, J. C., Montani, D., Nathan, S. D., Neubert, L., Price, L., & Kiely, D. G. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00259-x · Cited by 148
Diagnosis, course and management of hypersensitivity pneumonitis
Hamblin, M., Prosch, H., & Vašáková, M. (2022) · European Respiratory Review · doi:10.1183/16000617.0169-2021 · Cited by 147
Pulmonary hypertension associated with lung diseases
Shlobin, O. A., Adir, Y., Barberà, J. A., Cottin, V., Harari, S. A., Jutant, E., Pepke‐Żaba, J., Ghofrani, H. A., & Channick, R. N. (2024) · European Respiratory Journal · doi:10.1183/13993003.01200-2024 · Cited by 159
“In appropriate candidates, patients with bronchiectasis and PH should be referred for lung transplantation workup [162].”
Self-citationIdiopathic pulmonary fibrosis.
Koudstaal, T., & Wijsenbeek, M. S. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104166 · Cited by 105
Self-citationKoduri, G., & Solomon, J. J. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42640 · Cited by 108
“Guidelines recommend that patients who have severe and progressive RA-ILD that has not responded to appropriate treat-ment and who do not have extrapulmonary contraindications should be considered for lung transplantation (107).”
BackgroundExpected effect of the lung Composite Allocation Score system on US lung transplantation
Valapour, M., Lehr, C., Wey, A., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17160 · Cited by 78
“16 Development of the CAS provided an opportunity to be explicit about prioritization of ethical principles in the lung transplantation system, 17 with components selected through a hybrid approach using multicriteria decision-making methodologies and an analytical hierarchy process to elicit…”
MethodSelf-citationChristie, J. D., Raemdonck, D. E. V., & Fisher, A. J. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2401039 · Cited by 108
Lung transplantation for interstitial lung disease
Kapnadak, S. G., & Raghu, G. (2021) · European Respiratory Review · doi:10.1183/16000617.0017-2021 · Cited by 98
Self-citationEuropean Respiratory Society statement on frailty in adults with chronic lung disease
Osadnik, C. R., Brighton, L. J., Burtin, C., Cesari, M., Lahousse, L., Man, W. D., Marengoni, A., Šajnić, A., Singer, J. P., ter Beek, L., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00442-2023 · Cited by 96
“…for Heart and Lung Transplantation international consensus document for selection of lung transplant candidates states that frailty assessment should be considered part of a comprehensive transplant evaluation in recognition of its negative impact upon waitlist and post-transplant mortality [16].”
BackgroundBurgel, P., Southern, K. W., Addy, C., Battezzati, A., Berry, C. A., Bouchara, J., Brokaar, E. J., Brown, A. W., Azevedo, P., Durieu, I., et al. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.01.005 · Cited by 101
“Assessment of lung transplant candidates by transplant teams have been the subject of consensus documents [193] and practical guidelines [194], recognizing the specific needs of people with CF. Determining the optimal timing for lung transplantation remains difficult and may differ between…”
BackgroundGroup 3 Pulmonary Hypertension: From Bench to Bedside
Singh, N., Dorfmüller, P., Shlobin, O. A., & Ventetuolo, C. E. (2022) · Circulation Research · doi:10.1161/circresaha.121.319970 · Cited by 88
Self-citationMartin, C., Reynaud‐Gaubert, M., Hamidfar, R., Durieu, I., Murris‐Espin, M., Danner‐Boucher, I., Chiron, R., Leroy, S., Douvry, B., Grenet, D., et al. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.01.012 · Cited by 67
Nikkho, S. M., Richter, M. J., Shen, E., Abman, S. H., Antoniou, K., Chung, J. H., Fernandes, P., Hassoun, P. M., Lazarus, H. M., Olschewski, H., et al. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12127 · Cited by 70
Self-citationMcCarthy, C., Bonella, F., O’Callaghan, M., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.00725-2024 · Cited by 63
Reproductive health after thoracic transplantation: An ISHLT expert consensus statement
Kittleson, M. M., DeFilippis, E. M., Bhagra, C., Casale, J. P., Cauldwell, M., Coscia, L. A., D'Souza, R. D., Gaffney, N., Gerovasili, V., Ging, P., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.10.009 · Cited by 68
Mackintosh, J. A., Keir, G. J., Troy, L. K., Holland, A. E., Grainge, C., Chambers, D. C., Sandford, D., Jo, H. E., Glaspole, I., WILSHER, M. L., et al. (2024) · Respirology · doi:10.1111/resp.14656 · Cited by 54
Idiopathic inflammatory myopathies related lung disease in adults
Sehgal, S., Patel, A., Chatterjee, S., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00267-4 · Cited by 55
Mortality of patients with COPD
Halpin, D. M. G. (2024) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2375416 · Cited by 57
“The guidelines therefore recommend that they should be listed for transplantation if otherwise suitable [135].”
Sarcoidosis-associated pulmonary fibrosis: joining the dots
Bandyopadhyay, D., & Mirsaeidi, M. S. (2023) · European Respiratory Review · doi:10.1183/16000617.0085-2023 · Cited by 55
The changing landscape of pediatric lung transplantation
Avdimiretz, N., & Benden, C. (2022) · Clinical Transplantation · doi:10.1111/ctr.14634 · Cited by 49
Burgel, P., Paillasseur, J.-L., Durieu, I., Reynaud‐Gaubert, M., Hamidfar, R., Murris‐Espin, M., Danner‐Boucher, I., Chiron, R., Leroy, S., Douvry, B., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202312-1065oc · Cited by 47
Slambrouck, J. V., Raemdonck, D. E. V., Vos, R., Vanluyten, C., Vanstapel, A., Prisciandaro, E., Willems, L., Orlitová, M., Kaes, J., Jin, X., et al. (2022) · Cells · doi:10.3390/cells11040745 · Cited by 50
“A more in-depth analysis on treatment and prevention of PGD goes beyond the scope of this focus review and was summarized elsewhere [3,6,34,36,37].”
BackgroundTransplantation, bridging, and support technologies in pulmonary hypertension
Savale, L., Benazzo, A., Corris, P. A., Keshavjee, S. H., Levine, D. J., Mercier, O. M., Davis, R. D., & Granton, J. T. (2024) · European Respiratory Journal · doi:10.1183/13993003.01193-2024 · Cited by 47
“The suitability of a patient for transplant should be made by the transplant programme in collaboration with the PH team based on current accepted standards for recipient selection [79].”
Barbosa, M. T. R., & Chalmers, J. D. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104174 · Cited by 46
Martin, A. K., Mercier, O. M., Fritz, A. V., Gelzinis, T. A., Höetzenecker, K., Lindstedt, S., Marczin, N., Wilkey, B., Schecter, M. G., Lyster, H. S., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.08.027 · Cited by 46
Self-citationSwaminathan, A. C., Hellkamp, A. S., Neely, M. L., Bender, S. D., Paoletti, L., White, E. S., Palmer, S. M., Whelan, T. P. M., & Dilling, D. F. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202105-589oc · Cited by 39
Lehmann, M., Krishnan, R., Sucre, J. M. S., Kulkarni, H. S., Pineda, R., Anderson, C., Banovich, N. E., Behrsing, H. P., Dean, C. H., Haak, A. J., et al. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0479st · Cited by 45
Lung transplantation for COPD/pulmonary emphysema
Verleden, G. M., & Gottlieb, J. (2023) · European Respiratory Review · doi:10.1183/16000617.0116-2022 · Cited by 42
Sawinski, D. L., Lai, J. C., Pinney, S., Gray, A., Jackson, A. M., Stewart, D. E., Levine, D. J., Locke, J. E., Pomposelli, J. J., Hartwig, M. G., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2022.11.008 · Cited by 38
Self-citationCheng, X., Jiang, S., Pan, B., Xie, W., & Meng, J. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01964-3 · Cited by 40
“Lung transplantation is an effective treatment option for patients with end-stage IPF, but it is limited to a relatively young and healthy subset of patients [3].”
BackgroundBos, S., Murray, J. A., Marchetti, M., Cheng, G., Bergeron, A., Wolff, D., Sander, C. R., Sharma, A., Badawy, S. M., Perić, Z., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.01727-2023 · Cited by 37
Mudde, S. E., Schildkraut, J. A., Ammerman, N. C., de Vogel, C. P., de Steenwinkel, J. E. M., van Ingen, J., & Bax, H. I. (2022) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2022.10.015 · Cited by 34
Ringshausen, F. C., Sauer‐Heilborn, A., Büttner, T., Dittrich, A., Schwerk, N., Ius, F., Nährlich, L., Welte, T., & Greer, M. (2022) · European Respiratory Journal · doi:10.1183/13993003.01402-2022 · Cited by 34
Nathan, S. D., Chandel, A., Wang, Y., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2023.11.005 · Cited by 33
Development of the Lung Transplant Frailty Scale (LT-FS)
Singer, J. P., Christie, J. D., Diamond, J. M., Anderson, M. A., Benvenuto, L. J., Gao, Y., Arcasoy, S. M., Lederer, D. J., Calabrese, D. R., Wang, P., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2023.02.006 · Cited by 33
Self-citationLung Transplantation for Pulmonary Arterial Hypertension
Kolaitis, N. A. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.04.047 · Cited by 37
Self-citationGholamzadeh, M., Abtahi, H., & Safdari, R. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01823-2 · Cited by 30
“By 2019, more than 4,500 lung transplants were executed at 260 centers worldwide, according to the International Heart and Lung Transplant Association (ISHLT) [4].”
BackgroundSchiavi, E., Ryu, M. H., Martini, L., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202311-2145oc · Cited by 24
Marinescu, D.-C., Hague, C. J., Müller, N. L., Murphy, D. T., Churg, A., Wright, J. L., Al-Arnawoot, A., Bilawich, A.-M., Bourgouin, P., Cox, G., et al. (2025) · Radiology · doi:10.1148/radiol.241001 · Cited by 30
Arslan, A., Smith, J., Qureshi, M. R., Uysal, A., Patel, K., Herazo‐Maya, J. D., & Bandyopadhyay, D. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1306032 · Cited by 25
Shlobin, O. A., Shen, E., Wort, S. J., Piccari, L., Scandurra, J., Hassoun, P. M., Nikkho, S. M., & Nathan, S. D. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12310 · Cited by 25
Self-citationLung transplantation for interstitial lung disease: evolution over three decades
Leong, S. W., Bos, S., Lordan, J. L., Nair, A., Fisher, A. J., & Meachery, G. J. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001387 · Cited by 24
The Role of Pulmonary Function Testing in the Diagnosis and Management of COPD
Haynes, J. M., Kaminsky, D. A., & Ruppel, G. L. (2023) · Respiratory Care · doi:10.4187/respcare.10757 · Cited by 27
Subphenotypes of frailty in lung transplant candidates
Singer, J. P., Calfee, C. S., Delucchi, K., Diamond, J. M., Anderson, M. A., Benvenuto, L. A., Gao, Y., Wang, P., Arcasoy, S. M., Lederer, D. J., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.01.020 · Cited by 25
Self-citationKolaitis, N. A., Chen, H., Calabrese, D. R., Kumar, K., Obata, J., Bach, C., Golden, J. A., Simon, M. A. M., Kukreja, J., Hays, S. R., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202201-0217oc · Cited by 23
Self-citationHansmann, G., Diekmann, F., Chouvarine, P., Ius, F., Carlens, J., Schwerk, N., Warnecke, G., Vogel‐Claussen, J., Hohmann, D., Alten, T. A., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.10.014 · Cited by 22
Stepanova, M., Kumar, A. R., Brandt, P., Gundurao, N., Cusi, K. J., Qahtani, S. A., & Younossi, Z. M. (2023) · Diabetes Care · doi:10.2337/dc23-1085 · Cited by 19
Ghanem, O. M., Pita, A., Nazzal, M., Johnson, S. M., Diwan, T. S., Obeid, N. R., Croome, K. P., Lim, R., Quintini, C., Whitson, B. A., et al. (2024) · Surgical Endoscopy · doi:10.1007/s00464-024-10930-8 · Cited by 20
“The latest Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation criteria of eligibility included a BMI of ≥ 35 kg/m 2 as a relative contraindication for lung transplantation [72].”
BackgroundThomas, J., Chen, Q., Malas, J., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.01.014 · Cited by 20
Frailty predicts outcomes in cystic fibrosis patients listed for lung transplantation
Koutsokera, A., Sykes, J. R., Theou, O., Rockwood, K. J., Steinack, C., Derkenne, M.-F., Benden, C., Krueger, T., Chaparro, C., Aubert, J., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.07.017 · Cited by 21
“7) 28 (18-54) Age at LT, years 30 (18-63) 29 (18-56) Time on the waitlist, days 68.”
Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
Janić, M., Škrgat, S., Harlander, M., Lunder, M., Janež, A., Stoian, A. P., El‐Tanani, M., Maggio, V., & Rizzo, M. (2024) · Medicina · doi:10.3390/medicina60122030 · Cited by 27
“GLP-1 receptor agonists can be used in weight loss strategies prior to lung transplantation [96], as it has been shown that mortality risk increases with BMI > 35 kg/m 2 and that the magnitude of pre-transplant weight loss is directly correlated with improved post-transplant survival [97].”
Donor to recipient age matching in lung transplantation: A European experience
Pradère, P., Pavec, J. L., Morisset, S., Gerovasili, V., Kessler, R., Adlakha, A., Bunel, V., Santhanakrishnan, K., Demant, X., Roux, A., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.06.008 · Cited by 19
Luu, H. Y., Santos, J., Isaza, E., Brzeziński, M., & Kukreja, J. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1387 · Cited by 18
“While approximately 5% of recipients in the UNOS registry are reported to require ECLS post-LTx (8), this number is likely to increase in the future as higher-risk candidates become prioritized on the waitlist (27).”
Porras, M. C., Cuesta, V. M. M., Fernandez, D. I., et al. (2022) · Clinical Transplantation · doi:10.1111/ctr.14832 · Cited by 18
Bourgeois, N., Shallwani, S. M., Al-Huda, F. S., Mathur, S., Poirier, C. D., & Janaudis‐Ferreira, T. (2022) · Transplantation Direct · doi:10.1097/txd.0000000000001385 · Cited by 19
Wu, J., Li, C., Gao, P., Zhang, C., Zhang, P., Zhang, L., Dai, C., Zhang, K., Shi, B., Liu, M., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01515-3 · Cited by 17
“INTRODUCTION Lung transplantation is a potentially curative therapy for patients with end-stage pulmonary disease.(1) Nevertheless, the overall survival after a lung transplant is still inferior compared to other solid-organ transplantation modalities.”
BackgroundGhanem, O. M., Pita, A., Nazzal, M., Johnson, S. M., Diwan, T. S., Obeid, N. R., Croome, K. P., Lim, R., Quintini, C., Whitson, B. A., et al. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.04.013 · Cited by 17
Evolving Nutritional Needs in Cystic Fibrosis
Frantzen, T., Barsky, S., LaVecchia, G., Marowitz, M., & Wang, J. (2023) · Life · doi:10.3390/life13071431 · Cited by 18
“Continuous folic acid supplementation for at least 12 weeks and regular follow up with a CF dietitian is recommended [79].”
BackgroundOutcomes of Lung Transplant Candidates Aged ≥70 Years During the Lung Allocation Score Era
Zhou, A. L., Karius, A. K., Ruck, J. M., Shou, B. L., Larson, E. L., Casillan, A. J., Ha, J. S., Shah, P. D., Merlo, C. A., & Bush, E. L. (2023) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2023.04.046 · Cited by 17
Ehrsam, J. P., Schuurmans, M. M., Laager, M., Opitz, I., & İnci, İ. (2022) · Transplant International · doi:10.3389/ti.2022.10451 · Cited by 18
Lung transplantation in HIV-positive patients: a European retrospective cohort study
Rouzaud, C., Berastegui, C., Picard, C., Vos, R., Savale, L., Demant, X., Bertani, A., Verschuuren, E. A. M., Jaksch, P., Reed, A. K., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.00189-2022 · Cited by 19
Hayes, D., Avdimiretz, N., Brugha, R. E., Mullen, M. P., Paraskeva, M. A., Mıdyat, L., Solomon, M. P., Sweet, S. C., Melicoff, E., Danziger‐Isakov, L. A., et al. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.08.005 · Cited by 19
Self-citationObesity and Extracorporeal Membrane Oxygenation (ECMO): Analysis of Outcomes
Ripoll, J. G., ElSaban, M., Nabzdyk, C. S., Balakrishna, A., Villavicencio, M. A., Calderon-Rojas, R. D., Ortoleva, J. P., Chang, M. G., Bittner, E. A., & Ramakrishna, H. (2023) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2023.10.025 · Cited by 16
Chandel, A., King, C. S., Ignacio, R. V., Pastré, J., Shlobin, O. A., Khangoora, V. S., Aryal, S., NYQUIST, A. S., SINGHAL, A. L., Flaherty, K. R., et al. (2023) · ERJ Open Research · doi:10.1183/23120541.00124-2023 · Cited by 17
Self-citationKuczewski, M. G., Wasson, K., Hutchison, P. J., & Dilling, D. F. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.10.001 · Cited by 16
“Many of these are well-known such as requiring potential recipients of a liver transplant who suffer from alcohol substance use disorder to complete a treatment program for the disorder or for a cigarette smoker to demonstrate a sustained abstinence from nicotine before he is approved for a lung transplant.(6) Such re…”
BackgroundLung transplantation for lymphangioleiomyomatosis
Warrior, K., & Dilling, D. F. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.09.021 · Cited by 15
Interstitial Lung Disease in Rheumatoid Arthritis: A Review
AL-Baldawi, S. A. A., Salazar, G. Z., Zúñiga, D., Balasubramanian, S., & Mehmood, K. T. (2024) · Cureus · doi:10.7759/cureus.53632 · Cited by 16
“Lung transplantation should be considered for patients with severe and progressive RA-ILD who do not have extrapulmonary contraindications and who have not responded to appropriate treatment [76].”
BackgroundMangseth, H., Sikkeland, L. I. B., Durheim, M. T., et al. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02430-7 · Cited by 15
Extracorporeal life support as a bridge to lung transplantation: Where are we now?
Patterson, C. M., Shah, A. M., Rabin, J., DiChiacchio, L., Cypel, M., Höetzenecker, K., Catarino, P., & Lau, C. L. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.06.004 · Cited by 17
Self-citationVicaire, H., Pavec, J. L., Mercier, O. M., Montani, D., Boucly, A., Roche, A., Pradère, P., Dauriat, G., Feuillet, S., Pichon, J., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.06.001 · Cited by 16
Lehr, C. J., Wey, A. R., Skeans, M. A., Lease, E. D., & Valapour, M. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.02.012 · Cited by 16
“”(8) These principles were also upheld by the recently published International Society for Heart and Lung Transplantation guidelines on the selection of lung transplant candidates and the systems that allocate donor lungs.(25) This statement considered the principle of utility on the societal level and made recommenda…”
BackgroundSelf-citationChanges in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis
Oldham, J. M., Neely, M. L., WOJDYLA, D. M., Gulati, M., Li, P., Patel, D. C., Palmer, S. M., & Todd, J. L. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.02.018 · Cited by 20
Otani, I. M., & Ballow, M. C. (2024) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2024.12.024 · Cited by 15
Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis
Keith, R. C., & Nambiar, A. M. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241309795 · Cited by 20
“…a progressive phenotype, including fibrosing HP. Lung transplantation can improve the quality of life and survival in patients with IPF and PPF. 74,75 However, lung transplantation is only a viable option for a minority of patients with IPF/PPF. Factors such as age, comorbidities, overall health,…”
Herpes Virus Infection in Lung Transplantation: Diagnosis, Treatment and Prevention Strategies
Patrucco, F., Curtoni, A., Sidoti, F., Zanotto, E., Bondi, A., Albera, C., Boffini, M., Cavallo, R., Costa, C. S., & Solidoro, P. (2023) · Viruses · doi:10.3390/v15122326 · Cited by 14
“Lung transplantation represents a viable treatment option for many end-stage lung diseases [1]; chronic lung allograft dysfunction (CLAD), resulting in bronchiolitis obliterans syndrome (BOS) or restrictive allograft syndrome (RAS), is the most representative cause of mortality after the first year…”
Elia, D., Cassandro, R., Caminati, A., Luisi, F., & Harari, S. A. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104173 · Cited by 14
Lung Transplantation in a New Era in the Field of Cystic Fibrosis
Huang, W., Smith, A., Korotun, M., Iacono, A. T., & Wang, J. (2023) · Life · doi:10.3390/life13071600 · Cited by 15
“For example, referral criteria for patients who suffer from chronic obstructive pulmonary disease (COPD) include having a BODE index [19], a composite score measuring body mass index, forced expiratory volume in one second (FEV1), dyspnea, and six-minute walk distance equal to five or six with other features of increa…”
BackgroundMethodInfluentialPison, C., Tissot, A., Bernasconi, E., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1126697 · Cited by 13
The Management of Interstitial Lung Disease in the ICU: A Comprehensive Review
Dhanani, Z., & Gupta, R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226657 · Cited by 15
Virtual Physical Prehabilitation in Lung Transplant Candidates: A Proof-of-Concept Study
Bourgeois, N., Lands, L. C., Prévost, K., Poirier, C. D., & Janaudis‐Ferreira, T. (2024) · Transplant International · doi:10.3389/ti.2024.12355 · Cited by 14
Bordas-Martínez, J., Miedema, J., Mathot, B. J., Seghers, L., Galjaard, R. H., Raaijmakers, M. H. G. P., Aalbers, A. M., Wijsenbeek, M. S., Molina‐Molina, M., & Hellemons, M. E. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100054 · Cited by 13
“…available on how to handle patients with trILD, apart from the advice that patients with telomeropathy should “undergo detailed evaluation,” 28 it will differ between transplant centers how the results of such evaluation are weighed, affecting patient selection and therewith…”
Self-citationRadtke, T., Urquhart, D. S., Braun, J., Barry, P. J., Waller, I., Petch, N., Mei‐Zahav, M., Kramer, M. R., Hua-Huy, T., Dinh‐Xuan, A. T., et al. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202304-317oc · Cited by 13
Latorre‐Rodríguez, A. R., Razia, D., Omar, A. A., Bremner, R. M., & Mittal, S. K. (2023) · Transplantation Reviews · doi:10.1016/j.trre.2023.100796 · Cited by 13
Campagna, B. R., & Annunziato, R. A. (2023) · Pediatric Transplantation · doi:10.1111/petr.14497 · Cited by 14
Ding, Q., Chen, W., Chen, G., Zhu, Y., Yang, W.-W., & Ding, J.-R. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-3125 · Cited by 12
“However, in the scoring standards recognized for recipient selection among patients with ESLD worldwide, there is a lack of focus on nutritional status (20-22).”
Zysman, M., Mahay, G., Guibert, N. M., Barnig, C., Leroy, S., & Guilleminault, L. (2023) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2023.101035 · Cited by 15
Clinical Course of Interstitial Lung Disease in Patients With Rheumatoid Arthritis
Matteson, E. L., Bendstrup, E. M., Strek, M. E., & Dieudé, P. (2024) · ACR Open Rheumatology · doi:10.1002/acr2.11736 · Cited by 12
Interstitial Lung Disease Associated with Systemic Sclerosis
Mismetti, V., Si-Mohamed, S. A., & Cottin, V. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1786698 · Cited by 14
Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition
Bando, M., Homma, S., Date, H., Kishi, K., Yamauchi, H., Sakamoto, S., Miyamoto, A., Goto, Y., Nakayama, T., Azuma, A., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.02.014 · Cited by 12
Progressive Pulmonary Fibrosis: Where Are We Now?
Kang, H. K., & Song, J. W. (2023) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2023.0119 · Cited by 17
“However, because these studies were retrospective and limited by selection bias, ISHLT considers CTD to be a risk factor for poorer outcomes and recommends screening for extrapulmonary disease in collaboration with a multidisciplinary team 72,73 .”
Background
Metadata
- Authors
- Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., Hartwig, M. G., Kapnadak, S. G., Kolaitis, N. A., Kotloff, R. M., Patterson, C. M., Shlobin, O. A., Smith, P. J., Solé, A., Solomon, M., Weill, D., Wijsenbeek, M. S., Willemse, B. W. M., Arcasoy, S. M., & Ramos, K. J.
- Affiliations
- University of California, San Francisco (US)
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- St Vincent's Hospital Sydney (AU)
- Krishna Institute of Medical Sciences (IN)
- University of Toronto (CA)
- Medical University of South Carolina (US)
- Sahlgrenska University Hospital (SE)
- Duke University (US)
- University of Washington (US)
- University of Pennsylvania (US)
- Royal Papworth Hospital (GB)
- Inova Fairfax Hospital (US)
- Erasmus MC (NL)
- University Medical Center Groningen (NL)
- Columbia University (US)
- Corresponding author
- Leard, Lorriana E.
- ORCID
- Leard, Lorriana E.
- Holm, Are M.
- Valapour, Maryam
- Glanville, Allan R.
- Attawar, Sandeep
- Aversa, Meghan
- Christon, Lillian M.
- Cypel, Marcelo
- Dellgren, Göran
- Hartwig, Matthew G.
- Kapnadak, Siddhartha G.
- Kolaitis, Nicholas A.
- Patterson, Caroline M.
- Shlobin, Oksana A.
- Smith, Patrick J.
- Solomon, Melinda
- Wijsenbeek, Marlies S.
- Willemse, Brigitte W.M.
- Arcasoy, Selim M.
- Ramos, Kathleen J.
- Venue
- The Journal of Heart and Lung Transplantation
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 40
- Issue
- 11
- Pages
- 1349-1379
- ISSN
- 1053-2498 (ISSN-L)
- PMC
- PMC8979471
- OpenAlex
- W3183806681
- Semantic Scholar
- 428c0f28db10a88c62c6b907d2c92a02bac6b503
- Cited by
- 821
- References
- 363
- Citations by year
- 2026: 170 · 2025: 181 · 2024: 186 · 2023: 176 · 2022: 97 · 2021: 11
- FWCI
- 110.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Heart and Lung Transplantation (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Cystic Fibrosis Foundation
- Boomer Esiason Foundation
- Bristol-Myers Squibb
- United Therapeutics Corporation
- European Respiratory Society
- Vertex Pharmaceuticals
- Savara Pharmaceuticals
- Galecto
- ZonMw
- Astellas Pharma
- Lung Foundation Netherlands
- National Institutes of Health
- Health Resources and Services Administration
- National Heart, Lung, and Blood Institute (K23HL138154)
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Organ Donation and Transplantation
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lung transplantation, transplant candidate selection, advanced lung disease, referral timing, transplant evaluation, transplant listing, transplant ethics, risk stratification, International Society for Heart and Lung Transplantation
- MeSH terms
- Contraindications, Cystic Fibrosis, Humans, Societies, Medical, Lung Transplantation, Patient Selection, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-25 (prompt extract-v2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
